GlassScriptPhysician profile
Nicolas Patel
NPI 1134577166
$1,786.14
in general payments reported to CMS, 2019-2025
18 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $638 · 2023: $263 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $488.34 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $281.05 | 2022-2025 | Epclusa |
| Janssen Biotech, INC. | $228.12 | 2022-2025 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $163.95 | 2021-2022 | |
| Ardelyx, INC. | $141.24 | 2025 | Ibsrela |
| Qol Medical, LLC | $93.48 | 2025 | Sucraid |
| Abbvie INC. | $86.23 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $57.40 | 2025 | Voquezna |
| Novo Nordisk INC | $52.44 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $51.62 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.78 | 2022-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $17.95 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $17.71 | 2025 | Suflave, Sutab |
| Celltrion USA INC. | $15.56 | 2025 | Vegzelma |
| Genzyme Corporation | $15.51 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $14.64 | 2022 | |
| Aimmune Therapeutics, INC. | $14.18 | 2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $13.94 | 2023 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.